Clinical Trials Logo

Clinical Trial Summary

This is an open label, uncontrolled, Phase 4 study including 10 patients who present in hospital/urgent care setting with acquired methemoglobinemia. The population may include pediatric and adult patients (males and females of all ages are included). The study will run in both the EU and the US. The aim of the study is to confirm safety and efficacy of ProvayBlueTM for the treatment of acquired methemoglobinemia and has been requested by the US-FDA as a Post-Marketing requirements.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03395223
Study type Interventional
Source Provepharm SAS
Contact
Status Completed
Phase Phase 4
Start date July 6, 2018
Completion date August 31, 2020